• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Hainan Medical University >Correlation of the BRAF V600E and RAS mutations with clinicopathological characteristics of papillary thyroid cancer using TCGA database analysis
【24h】

Correlation of the BRAF V600E and RAS mutations with clinicopathological characteristics of papillary thyroid cancer using TCGA database analysis

机译：TCGA数据库分析BRAF V600E和RAS突变与甲状腺乳头状癌临床病理特征的相关性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To investigate the occurrence of BRAFV600E and RAS mutations in thyroid papillarycarcinoma (PTC) and to study their correlation with clinicopathological features of PTC.Methods Relevant information of PTC was downloaded and organized from The CancerGenome Atlas (TCGA) via cBioPortal, then the gene mutation and clinical information of402 PTC samples were analyzed. The correlation of BRAFV600E and RAS mutations withclinicopathological features and prognosis of PTC were subjected to univariate analysis.Secondly, we use Binary Logistic multivariate analysis to analyze the factors screened above.Results BRAFV600E mutation rate is 48.5% (195/402) and RAS mutation rate is 10.2% (41/402)in 402 cases of PTC. Univariate analysis showed that BRAFV600E mutation has nothing to dowith age and sex of the patient. There is a significant correlation among BRAFV600E mutationand lymph node metastasis, extrathyroidal invasion, staging, recurrence, progression andpathological subtypes in PTC. There is no significant correlation among RAS and age, sex,staging, recurrence, progression. There is a significant correlation among RAS and lymph nodemetastasis, extrathyroidal invasion and pathological subtypes in PTC. Multivariate logisticregression analysis indicated that there is a significant correlation among BRAFV600E mutationand extrathyroidal invasion, pathological subtypes in PTC. There is a significant correlationamong RAS and lymph node metastasis, extrathyroidal invasion and pathological subtypes inPTC. Conclusion The mutation rate of BRAFV600E was significantly higher than that of RAS inPTC. Mutations in BRAFV600E and RAS can be used as predictors of prognosis in PTC.
机译：目的：探讨BRAFV600E和RAS基因突变在甲状腺乳头状癌（PTC）中的发生，并探讨其与PTC临床病理特征的相关性。分析了402例PTC样品的突变和临床信息。进行BRAFV600E和RAS突变与临床病理特征和PTC预后的相关性单因素分析。其次，采用二元Logistic多变量分析方法分析上述因素，结果BRAFV600E突变率为48.5％（195/402），RAS突变率在402例PTC中为10.2％（41/402）。单因素分析表明，BRAFV600E突变与患者的年龄和性别无关。 PTC中BRAFV600E突变与淋巴结转移，甲状腺外侵袭，分期，复发，进展和病理亚型之间存在显着相关性。 RAS与年龄，性别，分期，复发，进展之间无显着相关性。 PTC与RAS和淋巴结转移，甲状腺外侵犯和病理亚型之间存在显着相关性。多元logistic回归分析表明，BRAFV600E突变与PTC中的甲状腺外侵袭，病理亚型之间存在显着相关性。 PTC与RAS和淋巴结转移，甲状腺外侵袭和病理亚型之间存在显着相关性。结论BRAFV600E的突变率明显高于RAS inPTC的突变率。 BRAFV600E和RAS中的突变可以用作PTC预后的预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号